Welcome to our dedicated page for Predictive Oncology SEC filings (Ticker: POAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Predictive Oncology Inc. (NASDAQ: POAI), which is changing its name to Axe Compute Inc. with an expected ticker change to AGPU, provides access to the company’s official regulatory disclosures. These documents include current reports on Form 8‑K, proxy statements, and other filings that describe material events, governance decisions, financing transactions, and listing matters.
Recent Form 8‑K filings detail several key developments. One 8‑K reports the adoption of a digital asset treasury strategy supported by private placements involving cash and in‑kind contributions of ATH, the native utility token of the Aethir ecosystem. Other 8‑Ks describe the launch and terms of these private placements, related registration rights agreements, and the use of proceeds to acquire ATH and support working capital and general corporate purposes. Additional 8‑Ks cover the 1‑for‑15 reverse stock split of the company’s common stock, actions taken to address Nasdaq listing requirements, and the company’s belief that it has regained compliance with Nasdaq’s minimum stockholders’ equity requirement.
The filings also document corporate governance and shareholder matters. A definitive proxy statement on Schedule DEF 14A outlines proposals for the annual meeting, including the election of directors, ratification of the independent auditor, amendments to the 2024 Equity Incentive Plan, approval of the issuance of shares upon exercise of pre‑funded warrants, and a non‑binding advisory vote on executive compensation. Another 8‑K describes shareholder approval of these items and the resulting increase in shares available under the equity plan.
One notable 8‑K filing reports the corporate name change from Predictive Oncology Inc. to Axe Compute Inc., effective December 11, 2025, and states that the Nasdaq ticker symbol is expected to change from POAI to AGPU on or about December 12, 2025. The filing notes that outstanding stock certificates remain valid and that the CUSIP number for the common stock will not change in connection with the name change.
Through Stock Titan, users can review these SEC filings in sequence and, with AI‑powered summaries, quickly understand the implications of complex documents such as 8‑Ks, proxy statements, and registration‑related supplements. This includes identifying how financing structures, equity plans, reverse splits, and digital asset strategies affect the company’s capital structure and governance over time.
Predictive Oncology (POAI) has scheduled a 2025 Special Meeting to vote on three board-backed items:
- Reverse Stock Split 1-for-15 – designed to lift the share price above Nasdaq’s US$1.00 minimum and remedy bid-price and equity deficiencies. Nasdaq has granted an extension until 8 Dec 2025.
- Nasdaq Proposal – authorize issuance of up to US$10 million in common stock under a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. Yorkville can purchase shares over 36 months at VWAP minus 4 %, potentially exceeding the 19.99 % “Exchange Cap.”
- Adjournment Proposal – permits the meeting to be postponed to secure sufficient votes.
The reverse split will consolidate every 15 shares into one, reduce the shares outstanding accordingly and round up fractional entitlements. While the move should improve marketability and preserve the Nasdaq listing, it increases the pool of authorized but unissued shares, raising dilution and anti-takeover concerns. The SEPA offers flexible working-capital financing, yet further share sales will dilute existing holders and depend on shareholder approval to lift the cap.
Failure to pass Proposals 1 or 2 risks delisting and limits access to the full SEPA facility. The board unanimously recommends voting FOR all three proposals.